Opportunity Information: Apply for RFA DA 26 019
The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)," under funding opportunity number RFA-DA-26-019 (CFDA/Assistance Listing 93.279). The focus is on supporting small businesses through the SBIR mechanism, using the R41/R42 phases, to develop or advance analytical instrumentation and methods that can keep up with fast-changing drug threats in the illicit supply. The application due date listed is February 19, 2025, and the opportunity was created on November 4, 2024. While the listing notes small businesses as the primary eligible applicants, it also indicates there are additional eligibility details and potentially other eligible applicant types described in the full Notice of Funding Opportunity (NOFO).
The central problem the opportunity is trying to solve is that the illicit drug supply is changing quickly, with substances such as xylazine and nitazenes already appearing and other novel compounds likely to emerge. Public health and public safety responses depend on being able to identify what is actually present in real-world samples, not just what is suspected. In many frontline settings, rapid test strips are commonly used because they are quick, sensitive, inexpensive, and generally accurate for the specific drugs they are designed to detect. The limitation is that strips only work when a strip exists for the compound in question, and new threats often show up before any widely available strip has been developed, validated, manufactured, and distributed.
Because of that gap, the opportunity emphasizes the need for "sensitive and sample agnostic methods." In practical terms, that points to analytical approaches and instrumentation that do not rely on a single known target in the way a dedicated immunoassay strip does. Instead, the goal is to support tools that can detect and characterize a broad range of compounds, including newly emerging drugs and adulterants, when analyzing real-world materials. This could include instrumentation and workflows intended for rapid or field-forward use, as well as laboratory-based systems that improve sensitivity, specificity, throughput, or the ability to identify unknowns. The overall intent is to strengthen detection capability when the drug landscape changes faster than targeted, strip-based tests can adapt.
The funding instrument is a grant, and the activity category is listed as Education and Health, reflecting the public health and biomedical relevance of drug detection. The "Clinical Trials Optional" designation indicates applicants may propose projects that include clinical trial elements if appropriate, but they are not required to do so. In many technology-development SBIR efforts, this typically means a project could focus purely on instrument and method development and validation using relevant samples, or it could also include human-subjects components if the proposed development and testing plan genuinely requires it and meets NIH requirements.
In short, this NIH opportunity is aimed at helping small businesses build the next generation of analytical instrumentation and alternative detection methods capable of keeping pace with emerging substances in the drug supply, especially when no dedicated test strips exist yet. The emphasis is on sensitivity, broad applicability across different sample types, and real-world relevance so that new and evolving threats can be identified and understood quickly enough to inform harm reduction, surveillance, and response efforts.Apply for RFA DA 26 019
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2024-11-04.
- Applicants must submit their applications by 2025-02-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this NIH funding opportunity?
This is a discretionary NIH grant opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)." It is issued under funding opportunity number RFA-DA-26-019 and is listed under CFDA/Assistance Listing 93.279.
What problem is the opportunity trying to solve?
The opportunity addresses the challenge that the illicit drug supply is changing quickly, with emerging substances (for example, xylazine and nitazenes) appearing in real-world samples and additional novel compounds likely to emerge. Public health and public safety responses depend on being able to identify what is actually present in samples, including substances that are new or unexpected.
Why are existing rapid test strips not enough on their own?
Rapid test strips are widely used in frontline settings because they are quick, sensitive, inexpensive, and generally accurate for the specific drugs they are designed to detect. Their key limitation is that they only work when a strip exists for the compound in question. New threats can appear before a test strip has been developed, validated, manufactured, and distributed at scale.
What types of projects does NIH want to support through this opportunity?
NIH is looking to support small business projects that develop or advance analytical instrumentation and methods that can keep up with fast-changing drug threats in the illicit supply. The intent is to build next-generation tools and workflows that improve detection and characterization of drugs and adulterants in real-world materials, especially when no dedicated strip-based test exists yet.
What does "instrumentation for alternative analytical methods" mean in this context?
Based on the description provided, it refers to analytical approaches and tools that are not limited to detecting only one known target (as is typical with a dedicated immunoassay test strip). Instead, it points toward methods and instrumentation designed to detect and characterize a broad range of compounds, including newly emerging drugs and adulterants.
What does "sensitive and sample agnostic methods" mean?
It means methods that can be highly sensitive while also working across different kinds of sample types (rather than being narrowly tailored to one substance or one specific sample format). The emphasis is on tools that can still be useful when the drug landscape shifts and the exact target compound is not known in advance.
Are field or rapid-use solutions relevant, or is this only for lab-based systems?
The opportunity description indicates interest in both: instrumentation and workflows intended for rapid or field-forward use, as well as laboratory-based systems that improve sensitivity, specificity, throughput, or the ability to identify unknowns.
What is the funding mechanism?
The funding mechanism is SBIR for small businesses, using the R41/R42 phases.
What do R41 and R42 refer to?
R41 and R42 refer to SBIR phased awards. The description indicates the opportunity supports projects under these phases to develop or advance instrumentation and analytical methods. (Specific phase requirements and expectations would be detailed in the full Notice of Funding Opportunity (NOFO).)
Who is eligible to apply?
The listing notes small businesses as the primary eligible applicants through the SBIR mechanism. It also notes there are additional eligibility details and potentially other eligible applicant types described in the full NOFO.
Is this opportunity limited to one specific emerging drug threat?
No. While examples such as xylazine and nitazenes are mentioned to illustrate the problem, the core focus is broader: developing detection capability that can keep pace with emerging substances and evolving threats, including compounds that may not yet have widely available targeted tests.
Does the project have to involve clinical trials?
No. The opportunity is labeled "Clinical Trials Optional," meaning applicants may propose projects that include clinical trial elements if appropriate, but they are not required to do so.
What does "Clinical Trials Optional" mean for technology development projects?
In this context, it indicates a project could focus purely on instrument and method development and validation using relevant samples, or it could include human-subjects components if the development and testing plan truly requires it and meets NIH requirements.
What kinds of outcomes is NIH aiming for?
The intent is to strengthen detection capability so that new and evolving threats can be identified and understood quickly enough to inform harm reduction, surveillance, and response efforts. The emphasis is on sensitivity, broad applicability across sample types, and real-world relevance.
What is the application due date?
The application due date listed is February 19, 2025.
When was this opportunity created?
The opportunity was created on November 4, 2024.
What is the funding instrument and activity category?
The funding instrument is a grant. The activity category is listed as Education and Health, reflecting the public health and biomedical relevance of drug detection.
Where can applicants find the full requirements and eligibility details?
The summary indicates that additional eligibility details and potentially other eligible applicant types are described in the full Notice of Funding Opportunity (NOFO). The NOFO is the authoritative source for complete requirements, expectations, and application instructions.
Browse more opportunities from the same category: Education, Health
Next opportunity: Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
Previous opportunity: RFI on Geologic Hydrogen Resource Exploration
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 26 019
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 26 019) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) Apply for PAR 25 104 Funding Number: PAR 25 104 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) Apply for PAR 25 103 Funding Number: PAR 25 103 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional) Apply for RFA DA 26 024 Funding Number: RFA DA 26 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) Apply for PAR 24 306 Funding Number: PAR 24 306 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,000 |
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Apply for PAR 25 175 Funding Number: PAR 25 175 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) Apply for PAR 24 311 Funding Number: PAR 24 311 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) Apply for PAR 25 145 Funding Number: PAR 25 145 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) Apply for PAR 25 153 Funding Number: PAR 25 153 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) Apply for PAR 25 221 Funding Number: PAR 25 221 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) Apply for PAR 24 325 Funding Number: PAR 24 325 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) Apply for PAR 25 079 Funding Number: PAR 25 079 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) Apply for PA 25 172 Funding Number: PA 25 172 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) Apply for PAR 25 237 Funding Number: PAR 25 237 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Apply for PAR 25 108 Funding Number: PAR 25 108 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional) Apply for PAR 25 201 Funding Number: PAR 25 201 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) Apply for PA 25 253 Funding Number: PA 25 253 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) Apply for PAR 25 081 Funding Number: PAR 25 081 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Apply for PAR 25 167 Funding Number: PAR 25 167 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) Apply for PAR 25 170 Funding Number: PAR 25 170 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) Apply for PAR 25 241 Funding Number: PAR 25 241 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 26 019", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.